Evidence map›Paper›PMID 41991313›Full record

Trial reportZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026

[Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia].

Z Y Liu, X G Chu, G P Dong, J Hao, Q S Chen, Y X Zhang

Abstract readRandomized Controlled TrialComparative StudyEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Z Y LiuDepartment of Hematology, Shanghai Jing'an District Beizhan Hospital, Shanghai 200070, China.
X G ChuDepartment of Hematology, Shanghai Jing'an District Beizhan Hospital, Shanghai 200070, China.
G P DongDepartment of Hematology, Shanghai Jing'an District Beizhan Hospital, Shanghai 200070, China.
J HaoDepartment of Hematology, Shanghai Jing'an District Beizhan Hospital, Shanghai 200070, China.
Q S ChenDepartment of Hematology, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong university School of Medicine, Shanghai 200025, China.
Y X ZhangDepartment of Hematology, Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiao Tong university School of Medicine, Shanghai 200025, China.

Funding

General Research Project of Health Scientific Research, Jing'an District, Shanghai 2021MS16
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAzacitidineLeukemia, Myeloid, AcuteAclarubicinAgedBridged Bicyclo Compounds, HeterocyclicCytarabineDecitabineFemaleGranulocyte Colony-Stimulating FactorHumansMaleProspective StudiesSulfonamidesTreatment OutcomeAclarubicinAzacitidineBridged Bicyclo Compounds, HeterocyclicCytarabineDecitabineGranulocyte Colony-Stimulating FactorSulfonamidesvenetoclaxAntitumor combination chemotherapy regimenElderlyLeukemia, myeloid, acuteRelapsed/refractoryVenetoclax

Identifiers

PMID41991313
PMCPMC13223667

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.